fenofibrate has been researched along with Cardiometabolic Syndrome in 86 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Cardiometabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Within a multicenter, randomized, open-label, cross-over study, 37 patients with metabolic syndrome received 6weeks' treatment with fenofibrate or extended-release niacin (ER niacin), with a 4weeks' wash-out period." | 9.20 | Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome. ( Adorni, MP; Benghozi, R; Calabresi, L; Damonte, E; Franceschini, G; Gomaraschi, M; Niesor, E; Ossoli, A; Veglia, F, 2015) |
| "Examine the effect of ABT-335 (fenofibric acid) on postprandial lipemia and susceptibility of plasma lipoproteins to Cu(++)-mediated oxidation in patients with metabolic syndrome." | 9.17 | Effect of ABT-335 (fenofibric acid) on meal-induced oxidative stress in patients with metabolic syndrome. ( Farkas-Epperson, M; Le, NA; Sweeney, ME; Virgil Brown, W; Wilson, PW, 2013) |
| "To compare the effects of n-3 long chain polyunsaturated fatty acids (n-3 LCPUFA), with those of fenofibrate, on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects." | 9.16 | Comparison of the effects of n-3 long chain polyunsaturated fatty acids and fenofibrate on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects. ( Bragt, MC; Mensink, RP, 2012) |
| "We examined the effects of fenofibrate and atorvastatin on very low density lipoprotein (VLDL) apolipoprotein (apo)E metabolism in the metabolic syndrome (MetS)." | 9.16 | Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome. ( Barrett, PH; Chan, DC; Ng, TW; Ooi, EM; Watts, GF, 2012) |
| "In this analysis of patients with mixed dyslipidemia, the lipid effects of ezetimibe plus fenofibrate were generally similar in metabolic syndrome patients versus those without metabolic syndrome." | 9.15 | Effects of coadministered ezetimibe plus fenofibrate in mixed dyslipidemic patients with metabolic syndrome. ( Bays, HE; Gumbiner, B; Macdonell, G; Shah, A; Taggart, WV, 2011) |
| "In subjects with the MetS, fenofibrate reduces systemic inflammation independent of improvements in lipoprotein metabolism and without changing insulin sensitivity." | 9.14 | Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. ( Belfort, R; Berria, R; Cornell, J; Cusi, K, 2010) |
| "To assess the efficacy and safety of coadministration of fenofibrate (NanoCrystal(R)) and ezetimibe in patients with type IIb dyslipidemia and the metabolic syndrome compared with administration of fenofibrate and ezetimibe alone (ClinicalTrials." | 9.14 | Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, ( Ansquer, JC; Bekaert, I; Guy, M; Hanefeld, M; Simon, A, 2009) |
| "Eleven men with metabolic syndrome were studied in a randomized, double-blind, crossover trial of 5-week intervention periods with placebo, fenofibrate (200 mg/day), and atorvastatin (40 mg/day)." | 9.14 | Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndrome. ( Barrett, PH; Chan, DC; Ji, J; Johnson, AG; Ooi, EM; Rye, KA; Watts, GF, 2009) |
| "8 mmol/L (500 mg/dL)) and ≥2 Adult Treatment Panel III criteria of the metabolic syndrome were randomized to daily fenofibrate (160 mg/d) or placebo for 12 weeks in a double-blind controlled clinical trial." | 9.14 | Heterogeneous postprandial lipoprotein responses in the metabolic syndrome, and response to fenofibrate therapy. ( Helenowski, IB; Rosenson, RS; Tangney, CC, 2010) |
| "To compare fenofibric acid (FA) + statin to respective monotherapies on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia." | 9.14 | The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia. ( Bays, HE; Kelly, MT; McKenney, JM; Obermeyer, K; Roth, EM; Setze, CM; Sleep, DJ; Thakker, KM, 2010) |
| "We explored whether cardiovascular disease (CVD) risk and the effects of fenofibrate differed in subjects with and without metabolic syndrome and according to various features of metabolic syndrome defined by the Adult Treatment Panel III (ATP III) in subjects with type 2 diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study." | 9.14 | Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. ( D'Emden, M; Ehnholm, C; Fulcher, G; Keech, A; O'Brien, R; Pardy, C; Scott, R; Taskinen, MR; Tse, D, 2009) |
| " This study investigates whether fenofibrate alters adiponectin levels in patients with hypertriglyceridemia and the metabolic syndrome, and examines the association of adiponectin with circulating inflammatory markers and whole blood cytokine production." | 9.14 | Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients. ( Rosenson, RS, 2009) |
| "The study involved a group of 242 metabolic syndrome patients with or without pre-diabetes and randomized to atorvastatin, fenofibrate, or placebo." | 9.14 | Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes. ( Bachowski, R; Gdula-Dymek, A; Krysiak, R; Okopien, B, 2010) |
| "To examine the effects of fenofibrate (160mg/d) therapy on fasting and postprandial cytokine production in subjects with metabolic syndrome and hypertriglyceridemia." | 9.13 | Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome. ( Helenowski, IB; Huskin, AL; Rademaker, AW; Rosenson, RS; Wolff, DA, 2008) |
| "Among hypertriglyceridemic subjects with the metabolic syndrome, fenofibrate therapy reduced Lp-PLA2 mass, and these changes were associated with fewer small LDL-Ps." | 9.13 | Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome. ( Rosenson, RS, 2008) |
| "We assessed the effect of orlistat and fenofibrate, alone or in combination, on plasma high-density lipoprotein (HDL) subfractions and plasma pre-beta1-HDL levels in overweight and obese subjects with metabolic syndrome (MetS)." | 9.13 | The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. ( Elisaf, MS; Filippatos, TD; Gazi, IF; Kiortsis, DN; Kostapanos, M; Liberopoulos, EN; Papavasiliou, EC; Tselepis, AD, 2008) |
| "The aim of this study was to determine the effects of fenofibrate (160 mg/day) on fasting and postprandial lipoproteins, oxidized fatty acids, and inflammatory mediators in subjects with hypertriglyceridemia and the metabolic syndrome." | 9.12 | Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. ( Helenowski, IB; Huskin, AL; Rademaker, AW; Rosenson, RS; Wolff, DA, 2007) |
| "The primary endpoint of this study was the effect of orlistat and fenofibrate, alone or in combination, on Lp-PLA(2) activity and LDL phenotype in overweight and obese patients (body mass index>28 kg/m(2)) with MetS." | 9.12 | The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. ( Athyros, VG; Elisaf, MS; Filippatos, TD; Gazi, IF; Kiortsis, DN; Liberopoulos, EN; Tselepis, AD, 2007) |
| "The aim of the present study was to investigate the association between changes in apoB (apolipoprotein B-100) kinetics and plasma PLTP (phospholipid transfer protein) and CETP (cholesteryl ester transfer protein) activities in men with MetS (the metabolic syndrome) treated with fenofibrate." | 9.12 | Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome. ( Barrett, PH; Chan, DC; Ji, J; Johnson, AG; Ooi, EM; Rye, KA; Watts, GF, 2006) |
| "The aim of this study was to evaluate whether and to what extent fenofibrate (F), metformin (M) or a combination of these drugs improve characteristics of the metabolic syndrome (MetS)." | 9.12 | Normalization of metabolic syndrome using fenofibrate, metformin or their combination. ( Kastelein, JJ; Nieuwdorp, M; Stroes, ES, 2007) |
| " Plasma insulin, antiinsulin antibodies, lipid parameters and the insulin sensitivity index (ISI) were measured at entry and after a 3-month therapy with 200 mg micronized fenofibrate daily." | 9.11 | Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. ( Belowski, D; Kalina, M; Kalina, Z; Kochanski, L; Okopien, B; Wysocki, J, 2004) |
| "In an open-label randomised study (the FenOrli study) we assessed the effect of orlistat and fenofibrate treatment, alone or in combination on reversing the diagnosis of the MetS (primary end-point) as well as on anthropometric and metabolic parameters (secondary end-points) in overweight and obese patients with MetS but no diabetes." | 9.11 | Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. ( Elisaf, MS; Filippatos, TD; Georgoula, M; Kiortsis, DN; Liberopoulos, EN; Mikhailidis, DP, 2005) |
| "The aim of this study was to assess the food-related efficacy of a new formulation of micronized fenofibrate coated on inert microgranules (FF-muG) for the treatment of hypertriglyceridemia in patients exhibiting the metabolic syndrome." | 9.11 | Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study. ( Bays, H; Davidson, MH; Doyle, R; Rhyne, J; Rotenberg, K; Stein, E, 2005) |
| "Improvement in endothelial function is predicted to improve insulin sensitivity, and this may be one mechanism by which fenofibrate decreases the incidence of coronary heart disease." | 9.11 | Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. ( Han, SH; Koh, KK; Quon, MJ; Shin, EK; Yeal Ahn, J, 2005) |
| "We designed a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial to evaluate the effects of treatment with pioglitazone and/or fenofibrate in patients with highly active antiretroviral therapy (HAART)-induced metabolic syndrome." | 9.11 | Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial. ( Doweiko, J; Gautam, S; Gavrila, A; Hsu, W; Karchmer, AW; Mantzoros, CS; Martin, L; Moses, AC; Tsiodras, S, 2005) |
| "This study aimed to determine the association between fenofibrate added to statin therapy and diabetic retinopathy progression." | 8.31 | Addition of fenofibrate to statins is associated with risk reduction of diabetic retinopathy progression in patients with type 2 diabetes and metabolic syndrome: A propensity-matched cohort study. ( Choi, J; Kim, NH; Kim, SG; Kim, YH; Lee, H, 2023) |
| "To investigate whether fenofibrate as add-on to statin treatment reduce persistent cardiovascular risk in adults with metabolic syndrome in a real world setting." | 7.91 | Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. ( Choi, J; Han, KH; Kim, NH; Kim, SG; Lee, J, 2019) |
| " Accordingly, the aim of this study was to determine the feasibility of peripheral blood mononuclear cells (PBMC) to study the effects of fenofibrate in patients with the metabolic syndrome." | 7.85 | Molecular effect of fenofibrate on PBMC gene transcription related to lipid metabolism in patients with metabolic syndrome. ( Cardona, F; Castellano-Castillo, D; Clemente-Postigo, M; Fernández-García, JC; Macias-Gonzalez, M; Moreno-Indias, I; Queipo-Ortuño, MI; Tinahones, FJ, 2017) |
| " Ten adolescents with hyperinsulinemia and dyslipidemia received therapy with metformin (500-1500 mg/daily) and micronized fenofibrate (160 mg/daily)." | 7.81 | Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience. ( Kalina, MA; Kalina-Faska, B; Mandera, M; Małecka Tendera, E; Skała-Zamorowska, E; Wilczek, M, 2015) |
| " Fructose administration resulted in significant increase in body weight, elevations of blood glucose, serum insulin, cholesterol, triglycerides, advanced glycation end products (AGEs), uric acid levels, insulin resistance index and blood pressure compared to control rats." | 7.80 | Ursodeoxycholic acid ameliorates fructose-induced metabolic syndrome in rats. ( Elshazly, SM; Mahmoud, AA, 2014) |
| "Fenofibrate therapy reduces serum triglycerides (TG) and increases high-density lipoprotein-cholesterol (HDL-C) and thus addresses the atherogenic dyslipidemia associated with metabolic syndrome (MetS)." | 7.77 | Association of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome status. ( An, P; Arnett, DK; Borecki, IB; Feitosa, MF; Hopkins, PN; Ketkar, S; Ordovas, JM; Straka, RJ, 2011) |
| "To compare the effect of high-dose rosuvastatin monotherapy with moderate dosing combined with fenofibrate or ω-3 fatty acids on the lipoprotein subfraction profile in patients with mixed dyslipidaemia and MetS." | 6.77 | Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. ( Agouridis, AP; Bairaktari, ET; Elisaf, MS; Kostapanos, MS; Kostara, C; Mikhailidis, DP; Tselepis, AD; Tsimihodimos, V, 2012) |
| "When fenofibrate was added to simvastatin therapy, HDL cholesterol increased significantly by 23%." | 6.71 | Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. ( Cater, NB; Filipchuk, N; Garcia-Garcia, AB; Grundy, SM; Ma, PT; Meguro, S; Vega, GL, 2003) |
| "The metabolic syndrome is characterized by insulin resistance and abnormal apolipoprotein AI (apoAI) and apolipoprotein B-100 (apoB) metabolism that may collectively accelerate atherosclerosis." | 6.71 | Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. ( Barrett, PH; Chan, DC; Croft, KD; Ji, J; Johnson, AG; Loehrer, F; Serone, AP; Watts, GF, 2003) |
| "Fenofibrate is a fibric acid derivative indicated for use in the treatment of primary hypercholesterolaemia, mixed dyslipidaemia and hypertriglyceridaemia in adults who have not responded to nonpharmacological measures." | 6.44 | Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. ( Croom, KF; Keating, GM, 2007) |
| "Fenofibrate also has a favorable impact on a number of nonlipid residual risk factors associated with type 2 diabetes and metabolic syndrome, mediated by peroxisome proliferator-activated receptor-alpha." | 6.44 | Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus. ( Steiner, G, 2008) |
| "Treatment with fenofibrate significantly reduced triglycerides, non-high density lipoprotein cholesterol (non-HDL-C), insulin levels and insulin resistance index (HOMA-IR) in MetS animals." | 5.43 | Fenofibrate Therapy Restores Antioxidant Protection and Improves Myocardial Insulin Resistance in a Rat Model of Metabolic Syndrome and Myocardial Ischemia: The Role of Angiotensin II. ( Carreón-Torres, E; Del Valle-Mondragón, L; Díaz-Díaz, E; Guarner-Lans, V; Ibarra-Lara, L; Rubio-Ruiz, ME; Sánchez-Aguilar, M; Sánchez-Mendoza, A; Soria-Castro, E; Vázquez-Meza, H, 2016) |
| "Fenofibrate treatment markedly suppressed the postprandial TG response in CD36KO along with decreased apoB-48 levels in plasma." | 5.36 | Fenofibrate reduces postprandial hypertriglyceridemia in CD36 knockout mice. ( Inagaki, M; Ishigami, M; Kawase, R; Komuro, I; Masuda, D; Nakagawa-Toyama, Y; Nakaoka, H; Nakatani, K; Nishida, M; Ohama, T; Sandoval, JC; Tochino, Y; Tsubakio-Yamamoto, K; Yamashita, S; Yuasa-Kawase, M, 2010) |
| "Fenofibrate treatment resulted in normalization of abnormal lipid profiles and a reduction in Fb level." | 5.35 | Effects of fenofibrate treatment on prothrombotic state in patients with metabolic syndrome in relation to smoking and diabetes. ( Bukowska, H; Chełstowski, K; Jastrzebska, M; Klimek, K; Mierzecki, A, 2009) |
| " Some PPARα-specific agonists, such as Wy14643 and fenofibrate, have been applied in metabolic syndrome treatment, which might own potential in wider application." | 5.22 | PPARα: An emerging target of metabolic syndrome, neurodegenerative and cardiovascular diseases. ( Li, PF; Lin, Y; Wang, Y, 2022) |
| "Within a multicenter, randomized, open-label, cross-over study, 37 patients with metabolic syndrome received 6weeks' treatment with fenofibrate or extended-release niacin (ER niacin), with a 4weeks' wash-out period." | 5.20 | Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome. ( Adorni, MP; Benghozi, R; Calabresi, L; Damonte, E; Franceschini, G; Gomaraschi, M; Niesor, E; Ossoli, A; Veglia, F, 2015) |
| "Examine the effect of ABT-335 (fenofibric acid) on postprandial lipemia and susceptibility of plasma lipoproteins to Cu(++)-mediated oxidation in patients with metabolic syndrome." | 5.17 | Effect of ABT-335 (fenofibric acid) on meal-induced oxidative stress in patients with metabolic syndrome. ( Farkas-Epperson, M; Le, NA; Sweeney, ME; Virgil Brown, W; Wilson, PW, 2013) |
| "We examined the effects of fenofibrate and atorvastatin on very low density lipoprotein (VLDL) apolipoprotein (apo)E metabolism in the metabolic syndrome (MetS)." | 5.16 | Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome. ( Barrett, PH; Chan, DC; Ng, TW; Ooi, EM; Watts, GF, 2012) |
| "To compare the effects of n-3 long chain polyunsaturated fatty acids (n-3 LCPUFA), with those of fenofibrate, on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects." | 5.16 | Comparison of the effects of n-3 long chain polyunsaturated fatty acids and fenofibrate on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects. ( Bragt, MC; Mensink, RP, 2012) |
| "In this analysis of patients with mixed dyslipidemia, the lipid effects of ezetimibe plus fenofibrate were generally similar in metabolic syndrome patients versus those without metabolic syndrome." | 5.15 | Effects of coadministered ezetimibe plus fenofibrate in mixed dyslipidemic patients with metabolic syndrome. ( Bays, HE; Gumbiner, B; Macdonell, G; Shah, A; Taggart, WV, 2011) |
| "To assess the efficacy and safety of coadministration of fenofibrate (NanoCrystal(R)) and ezetimibe in patients with type IIb dyslipidemia and the metabolic syndrome compared with administration of fenofibrate and ezetimibe alone (ClinicalTrials." | 5.14 | Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, ( Ansquer, JC; Bekaert, I; Guy, M; Hanefeld, M; Simon, A, 2009) |
| "Eleven men with metabolic syndrome were studied in a randomized, double-blind, crossover trial of 5-week intervention periods with placebo, fenofibrate (200 mg/day), and atorvastatin (40 mg/day)." | 5.14 | Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndrome. ( Barrett, PH; Chan, DC; Ji, J; Johnson, AG; Ooi, EM; Rye, KA; Watts, GF, 2009) |
| "To compare fenofibric acid (FA) + statin to respective monotherapies on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia." | 5.14 | The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia. ( Bays, HE; Kelly, MT; McKenney, JM; Obermeyer, K; Roth, EM; Setze, CM; Sleep, DJ; Thakker, KM, 2010) |
| "We explored whether cardiovascular disease (CVD) risk and the effects of fenofibrate differed in subjects with and without metabolic syndrome and according to various features of metabolic syndrome defined by the Adult Treatment Panel III (ATP III) in subjects with type 2 diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study." | 5.14 | Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. ( D'Emden, M; Ehnholm, C; Fulcher, G; Keech, A; O'Brien, R; Pardy, C; Scott, R; Taskinen, MR; Tse, D, 2009) |
| "The study involved a group of 242 metabolic syndrome patients with or without pre-diabetes and randomized to atorvastatin, fenofibrate, or placebo." | 5.14 | Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes. ( Bachowski, R; Gdula-Dymek, A; Krysiak, R; Okopien, B, 2010) |
| "In subjects with the MetS, fenofibrate reduces systemic inflammation independent of improvements in lipoprotein metabolism and without changing insulin sensitivity." | 5.14 | Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. ( Belfort, R; Berria, R; Cornell, J; Cusi, K, 2010) |
| "8 mmol/L (500 mg/dL)) and ≥2 Adult Treatment Panel III criteria of the metabolic syndrome were randomized to daily fenofibrate (160 mg/d) or placebo for 12 weeks in a double-blind controlled clinical trial." | 5.14 | Heterogeneous postprandial lipoprotein responses in the metabolic syndrome, and response to fenofibrate therapy. ( Helenowski, IB; Rosenson, RS; Tangney, CC, 2010) |
| " This study investigates whether fenofibrate alters adiponectin levels in patients with hypertriglyceridemia and the metabolic syndrome, and examines the association of adiponectin with circulating inflammatory markers and whole blood cytokine production." | 5.14 | Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients. ( Rosenson, RS, 2009) |
| "To examine the effects of fenofibrate (160mg/d) therapy on fasting and postprandial cytokine production in subjects with metabolic syndrome and hypertriglyceridemia." | 5.13 | Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome. ( Helenowski, IB; Huskin, AL; Rademaker, AW; Rosenson, RS; Wolff, DA, 2008) |
| "We assessed the effect of orlistat and fenofibrate, alone or in combination, on plasma high-density lipoprotein (HDL) subfractions and plasma pre-beta1-HDL levels in overweight and obese subjects with metabolic syndrome (MetS)." | 5.13 | The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. ( Elisaf, MS; Filippatos, TD; Gazi, IF; Kiortsis, DN; Kostapanos, M; Liberopoulos, EN; Papavasiliou, EC; Tselepis, AD, 2008) |
| "Among hypertriglyceridemic subjects with the metabolic syndrome, fenofibrate therapy reduced Lp-PLA2 mass, and these changes were associated with fewer small LDL-Ps." | 5.13 | Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome. ( Rosenson, RS, 2008) |
| "The aim of the present study was to investigate the association between changes in apoB (apolipoprotein B-100) kinetics and plasma PLTP (phospholipid transfer protein) and CETP (cholesteryl ester transfer protein) activities in men with MetS (the metabolic syndrome) treated with fenofibrate." | 5.12 | Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome. ( Barrett, PH; Chan, DC; Ji, J; Johnson, AG; Ooi, EM; Rye, KA; Watts, GF, 2006) |
| "The primary endpoint of this study was the effect of orlistat and fenofibrate, alone or in combination, on Lp-PLA(2) activity and LDL phenotype in overweight and obese patients (body mass index>28 kg/m(2)) with MetS." | 5.12 | The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. ( Athyros, VG; Elisaf, MS; Filippatos, TD; Gazi, IF; Kiortsis, DN; Liberopoulos, EN; Tselepis, AD, 2007) |
| "The aim of this study was to evaluate whether and to what extent fenofibrate (F), metformin (M) or a combination of these drugs improve characteristics of the metabolic syndrome (MetS)." | 5.12 | Normalization of metabolic syndrome using fenofibrate, metformin or their combination. ( Kastelein, JJ; Nieuwdorp, M; Stroes, ES, 2007) |
| "The aim of this study was to determine the effects of fenofibrate (160 mg/day) on fasting and postprandial lipoproteins, oxidized fatty acids, and inflammatory mediators in subjects with hypertriglyceridemia and the metabolic syndrome." | 5.12 | Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. ( Helenowski, IB; Huskin, AL; Rademaker, AW; Rosenson, RS; Wolff, DA, 2007) |
| " Plasma insulin, antiinsulin antibodies, lipid parameters and the insulin sensitivity index (ISI) were measured at entry and after a 3-month therapy with 200 mg micronized fenofibrate daily." | 5.11 | Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. ( Belowski, D; Kalina, M; Kalina, Z; Kochanski, L; Okopien, B; Wysocki, J, 2004) |
| "We designed a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial to evaluate the effects of treatment with pioglitazone and/or fenofibrate in patients with highly active antiretroviral therapy (HAART)-induced metabolic syndrome." | 5.11 | Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial. ( Doweiko, J; Gautam, S; Gavrila, A; Hsu, W; Karchmer, AW; Mantzoros, CS; Martin, L; Moses, AC; Tsiodras, S, 2005) |
| "Improvement in endothelial function is predicted to improve insulin sensitivity, and this may be one mechanism by which fenofibrate decreases the incidence of coronary heart disease." | 5.11 | Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. ( Han, SH; Koh, KK; Quon, MJ; Shin, EK; Yeal Ahn, J, 2005) |
| "The aim of this study was to assess the food-related efficacy of a new formulation of micronized fenofibrate coated on inert microgranules (FF-muG) for the treatment of hypertriglyceridemia in patients exhibiting the metabolic syndrome." | 5.11 | Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study. ( Bays, H; Davidson, MH; Doyle, R; Rhyne, J; Rotenberg, K; Stein, E, 2005) |
| "In an open-label randomised study (the FenOrli study) we assessed the effect of orlistat and fenofibrate treatment, alone or in combination on reversing the diagnosis of the MetS (primary end-point) as well as on anthropometric and metabolic parameters (secondary end-points) in overweight and obese patients with MetS but no diabetes." | 5.11 | Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. ( Elisaf, MS; Filippatos, TD; Georgoula, M; Kiortsis, DN; Liberopoulos, EN; Mikhailidis, DP, 2005) |
| " Evidence from the Fenofibrate Intervention and Event Lowering in Diabetes study suggests that fenofibrate reduces the risk of long-term macrovascular and microvascular type 2 diabetic complications, especially in patients demonstrating features of the metabolic syndrome." | 4.85 | Clinical insights from the Fenofibrate Intervention and Event Lowering in Diabetes study: a community practice perspective. ( Toth, PP, 2009) |
| "This study aimed to determine the association between fenofibrate added to statin therapy and diabetic retinopathy progression." | 4.31 | Addition of fenofibrate to statins is associated with risk reduction of diabetic retinopathy progression in patients with type 2 diabetes and metabolic syndrome: A propensity-matched cohort study. ( Choi, J; Kim, NH; Kim, SG; Kim, YH; Lee, H, 2023) |
| "To investigate whether fenofibrate as add-on to statin treatment reduce persistent cardiovascular risk in adults with metabolic syndrome in a real world setting." | 3.91 | Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. ( Choi, J; Han, KH; Kim, NH; Kim, SG; Lee, J, 2019) |
| " Accordingly, the aim of this study was to determine the feasibility of peripheral blood mononuclear cells (PBMC) to study the effects of fenofibrate in patients with the metabolic syndrome." | 3.85 | Molecular effect of fenofibrate on PBMC gene transcription related to lipid metabolism in patients with metabolic syndrome. ( Cardona, F; Castellano-Castillo, D; Clemente-Postigo, M; Fernández-García, JC; Macias-Gonzalez, M; Moreno-Indias, I; Queipo-Ortuño, MI; Tinahones, FJ, 2017) |
| " Ten adolescents with hyperinsulinemia and dyslipidemia received therapy with metformin (500-1500 mg/daily) and micronized fenofibrate (160 mg/daily)." | 3.81 | Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience. ( Kalina, MA; Kalina-Faska, B; Mandera, M; Małecka Tendera, E; Skała-Zamorowska, E; Wilczek, M, 2015) |
| " Fructose administration resulted in significant increase in body weight, elevations of blood glucose, serum insulin, cholesterol, triglycerides, advanced glycation end products (AGEs), uric acid levels, insulin resistance index and blood pressure compared to control rats." | 3.80 | Ursodeoxycholic acid ameliorates fructose-induced metabolic syndrome in rats. ( Elshazly, SM; Mahmoud, AA, 2014) |
| "Fenofibrate therapy reduces serum triglycerides (TG) and increases high-density lipoprotein-cholesterol (HDL-C) and thus addresses the atherogenic dyslipidemia associated with metabolic syndrome (MetS)." | 3.77 | Association of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome status. ( An, P; Arnett, DK; Borecki, IB; Feitosa, MF; Hopkins, PN; Ketkar, S; Ordovas, JM; Straka, RJ, 2011) |
| " We investigated the influences of CRP polymorphisms on baseline CRP levels and fenofibrate-induced CRP changes in subjects with the metabolic syndrome." | 3.74 | Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: the GOLDN study. ( Arnett, DK; Hixson, JE; Lai, CQ; Ordovas, JM; Parnell, LD; Peacock, JM; Province, MA; Shen, J; Straka, RJ; Tsai, MY, 2008) |
| "Seventy five patients with metabolic syndrome aged 40-59 years were included into an open study with parallel groups in which the following combinations of lipid lowering and antihypertensive drugs were used for sweeksinch: atorvastatin + perindopril (n=17, group 1); simvastatin + atenolol (n=17, group 2); fenofibrate + atenolol (n=21, group 3), and simvastatin + indapamide (n=20, group 4)." | 3.72 | [Effect of combined antihypertensive and lipid lowering therapy on the level of coronary risk and tissue insulin resistance in patients with metabolic syndrome]. ( Khadipash, LA; Kiseleva, NV; Kosmatova, OV; Mamedov, MN; Oganov, RG; Perova, NV, 2003) |
| "To compare the effect of high-dose rosuvastatin monotherapy with moderate dosing combined with fenofibrate or ω-3 fatty acids on the lipoprotein subfraction profile in patients with mixed dyslipidaemia and MetS." | 2.77 | Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. ( Agouridis, AP; Bairaktari, ET; Elisaf, MS; Kostapanos, MS; Kostara, C; Mikhailidis, DP; Tselepis, AD; Tsimihodimos, V, 2012) |
| "Patients with the metabolic syndrome are more likely to develop type 2 diabetes and may have an increased risk of cardiovascular disease (CVD) events." | 2.76 | Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. ( Colman, PG; Davis, TM; Donoghoe, M; Fulcher, G; Keech, AC; Manning, P; O'Brien, R; Pardy, C; Scott, R; Taskinen, MR; Watts, GF, 2011) |
| "Recently, nephrolithiasis has been reported to be involved with renal manifestation of metabolic syndrome." | 2.73 | Relationship between insulin resistance and low urinary pH in patients with gout, and effects of PPARalpha agonists on urine pH. ( Inokuchi, T; Ka, T; Kobayashi, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamamoto, T, 2007) |
| "When fenofibrate was added to simvastatin therapy, HDL cholesterol increased significantly by 23%." | 2.71 | Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. ( Cater, NB; Filipchuk, N; Garcia-Garcia, AB; Grundy, SM; Ma, PT; Meguro, S; Vega, GL, 2003) |
| "The metabolic syndrome is characterized by insulin resistance and abnormal apolipoprotein AI (apoAI) and apolipoprotein B-100 (apoB) metabolism that may collectively accelerate atherosclerosis." | 2.71 | Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. ( Barrett, PH; Chan, DC; Croft, KD; Ji, J; Johnson, AG; Loehrer, F; Serone, AP; Watts, GF, 2003) |
| "Patients with type 2 diabetes or metabolic syndrome remain at high residual risk of cardiovascular events even after intensive statin therapy." | 2.45 | Combination statin-fibrate therapy: safety aspects. ( Franssen, R; Kastelein, JJ; Stroes, ES; Vergeer, M, 2009) |
| "Fenofibrate is a fibric acid derivative indicated for use in the treatment of primary hypercholesterolaemia, mixed dyslipidaemia and hypertriglyceridaemia in adults who have not responded to nonpharmacological measures." | 2.44 | Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. ( Croom, KF; Keating, GM, 2007) |
| "Fenofibrate also has a favorable impact on a number of nonlipid residual risk factors associated with type 2 diabetes and metabolic syndrome, mediated by peroxisome proliferator-activated receptor-alpha." | 2.44 | Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus. ( Steiner, G, 2008) |
| " Recently conducted metabolic and pharmacokinetic drug-drug interaction studies using gemfibrozil or fenofibrate in combination with five commonly used statins demonstrated a widely different drug interaction potential for these two fibrates." | 2.43 | Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. ( Davidson, MH, 2006) |
| "The metabolic syndrome and type 2 diabetes mellitus are both becoming more prevalent, and both increase the risk of cardiovascular disease." | 2.43 | Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. ( Nesto, RW, 2005) |
| "Dyslipidemia is characterized by increased triglyceride-rich lipoproteins; low high-density lipoprotein cholesterol; small, dense low-density lipoprotein particles; increased postprandial lipemia; and abnormal apolipoprotein A1 and B metabolism." | 2.42 | Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome. ( Cottrell, DA; Falko, JM; Marshall, BJ, 2003) |
| "Identification and treatment of the metabolic syndrome is of enormous public health importance because it is associated with a marked elevation in coronary heart disease risk and affects nearly 25% of adults in the United States." | 2.42 | Fibrates for treatment of the metabolic syndrome. ( Maki, KC, 2004) |
| "Metabolic syndrome is associated with increased cardiovascular risk." | 2.41 | [Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome]. ( Idzior-Waluś, B, 2001) |
| "Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease and important risk factor for cardiac diseases, diabetes and extrahepatic cancers." | 1.56 | Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome. ( Hao, L; Hao, S; Sun, H; Wang, Z; Yu, P; Zhang, M; Zhang, X, 2020) |
| "In Ppara-null mice, MFD treatment increased body weight, adipose tissue, serum TG and impaired glucose tolerance." | 1.48 | PPARα-independent action against metabolic syndrome development by fibrates is mediated by inhibition of STAT3 signalling. ( Dai, M; Gonzalez, FJ; Hua, H; Huang, J; Lin, H; Liu, A; Liu, L; Wang, F; Xi, Y; Xu, G; Yang, J; Zhao, T, 2018) |
| "Treatment with fenofibrate significantly reduced triglycerides, non-high density lipoprotein cholesterol (non-HDL-C), insulin levels and insulin resistance index (HOMA-IR) in MetS animals." | 1.43 | Fenofibrate Therapy Restores Antioxidant Protection and Improves Myocardial Insulin Resistance in a Rat Model of Metabolic Syndrome and Myocardial Ischemia: The Role of Angiotensin II. ( Carreón-Torres, E; Del Valle-Mondragón, L; Díaz-Díaz, E; Guarner-Lans, V; Ibarra-Lara, L; Rubio-Ruiz, ME; Sánchez-Aguilar, M; Sánchez-Mendoza, A; Soria-Castro, E; Vázquez-Meza, H, 2016) |
| "Fenofibrate has a well-known efficacy to reduce cholesterol and triglycerides." | 1.43 | Hepatotoxic effects of fenofibrate in spontaneously hypertensive rats expressing human C-reactive protein. ( Kazdová, L; Kůdela, M; Landa, V; Malínská, H; Marková, I; Mlejnek, P; Oliyarnyk, O; Pravenec, M; Šilhavý, J; Šimáková, M; Škop, V; Trnovská, J; Zídek, V, 2016) |
| "Fenofibrate treatment markedly suppressed the postprandial TG response in CD36KO along with decreased apoB-48 levels in plasma." | 1.36 | Fenofibrate reduces postprandial hypertriglyceridemia in CD36 knockout mice. ( Inagaki, M; Ishigami, M; Kawase, R; Komuro, I; Masuda, D; Nakagawa-Toyama, Y; Nakaoka, H; Nakatani, K; Nishida, M; Ohama, T; Sandoval, JC; Tochino, Y; Tsubakio-Yamamoto, K; Yamashita, S; Yuasa-Kawase, M, 2010) |
| "Fenofibrate treatment resulted in normalization of abnormal lipid profiles and a reduction in Fb level." | 1.35 | Effects of fenofibrate treatment on prothrombotic state in patients with metabolic syndrome in relation to smoking and diabetes. ( Bukowska, H; Chełstowski, K; Jastrzebska, M; Klimek, K; Mierzecki, A, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 51 (59.30) | 29.6817 |
| 2010's | 28 (32.56) | 24.3611 |
| 2020's | 7 (8.14) | 2.80 |
| Authors | Studies |
|---|---|
| Romero, FA | 1 |
| Jones, CT | 1 |
| Xu, Y | 1 |
| Fenaux, M | 1 |
| Halcomb, RL | 1 |
| Zhang, M | 1 |
| Wang, Z | 1 |
| Hao, S | 1 |
| Hao, L | 1 |
| Zhang, X | 1 |
| Yu, P | 1 |
| Sun, H | 1 |
| Vuorio, A | 1 |
| Brinck, J | 1 |
| Kovanen, PT | 1 |
| van Walree, ES | 1 |
| Jansen, IE | 1 |
| Bell, NY | 1 |
| Savage, JE | 1 |
| de Leeuw, C | 1 |
| Nieuwdorp, M | 2 |
| van der Sluis, S | 1 |
| Posthuma, D | 1 |
| Lin, Y | 1 |
| Wang, Y | 1 |
| Li, PF | 1 |
| Kim, NH | 2 |
| Choi, J | 2 |
| Kim, YH | 1 |
| Lee, H | 1 |
| Kim, SG | 2 |
| Han, KH | 1 |
| Lee, J | 1 |
| Nabil, M | 1 |
| El Demellawy, MA | 1 |
| Mahmoud, MF | 1 |
| Mahmoud, AAA | 1 |
| Hua, H | 1 |
| Yang, J | 1 |
| Lin, H | 1 |
| Xi, Y | 1 |
| Dai, M | 1 |
| Xu, G | 1 |
| Wang, F | 1 |
| Liu, L | 1 |
| Zhao, T | 1 |
| Huang, J | 1 |
| Gonzalez, FJ | 1 |
| Liu, A | 1 |
| Le, NA | 1 |
| Farkas-Epperson, M | 1 |
| Sweeney, ME | 1 |
| Wilson, PW | 1 |
| Virgil Brown, W | 1 |
| van den Hoek, AM | 1 |
| van der Hoorn, JW | 1 |
| Maas, AC | 1 |
| van den Hoogen, RM | 1 |
| van Nieuwkoop, A | 1 |
| Droog, S | 1 |
| Offerman, EH | 1 |
| Pieterman, EJ | 1 |
| Havekes, LM | 1 |
| Princen, HM | 1 |
| Mahmoud, AA | 1 |
| Elshazly, SM | 1 |
| Kalina, MA | 1 |
| Wilczek, M | 1 |
| Kalina-Faska, B | 1 |
| Skała-Zamorowska, E | 1 |
| Mandera, M | 1 |
| Małecka Tendera, E | 1 |
| Gomaraschi, M | 1 |
| Ossoli, A | 1 |
| Adorni, MP | 1 |
| Damonte, E | 1 |
| Niesor, E | 1 |
| Veglia, F | 1 |
| Franceschini, G | 1 |
| Benghozi, R | 1 |
| Calabresi, L | 1 |
| Márk, L | 1 |
| Dani, G | 1 |
| Škop, V | 1 |
| Trnovská, J | 1 |
| Oliyarnyk, O | 1 |
| Marková, I | 1 |
| Malínská, H | 1 |
| Kazdová, L | 1 |
| Zídek, V | 1 |
| Landa, V | 1 |
| Mlejnek, P | 1 |
| Šimáková, M | 1 |
| Kůdela, M | 1 |
| Pravenec, M | 1 |
| Šilhavý, J | 1 |
| Ibarra-Lara, L | 1 |
| Sánchez-Aguilar, M | 1 |
| Sánchez-Mendoza, A | 1 |
| Del Valle-Mondragón, L | 1 |
| Soria-Castro, E | 1 |
| Carreón-Torres, E | 1 |
| Díaz-Díaz, E | 1 |
| Vázquez-Meza, H | 1 |
| Guarner-Lans, V | 1 |
| Rubio-Ruiz, ME | 1 |
| Moreno-Indias, I | 1 |
| Tinahones, FJ | 2 |
| Clemente-Postigo, M | 1 |
| Castellano-Castillo, D | 1 |
| Fernández-García, JC | 1 |
| Macias-Gonzalez, M | 1 |
| Queipo-Ortuño, MI | 2 |
| Cardona, F | 2 |
| Franssen, R | 1 |
| Vergeer, M | 1 |
| Stroes, ES | 2 |
| Kastelein, JJ | 2 |
| Chan, DC | 5 |
| Watts, GF | 6 |
| Ooi, EM | 4 |
| Ji, J | 4 |
| Johnson, AG | 4 |
| Barrett, PH | 5 |
| Ginsberg, HN | 1 |
| Ramakrishnan, R | 1 |
| Scott, R | 2 |
| O'Brien, R | 2 |
| Fulcher, G | 2 |
| Pardy, C | 2 |
| D'Emden, M | 1 |
| Tse, D | 1 |
| Taskinen, MR | 2 |
| Ehnholm, C | 1 |
| Keech, A | 1 |
| Rosenson, RS | 5 |
| Sacks, FM | 1 |
| Steiner, G | 1 |
| Jones, PH | 1 |
| Ansquer, JC | 1 |
| Bekaert, I | 1 |
| Guy, M | 1 |
| Hanefeld, M | 1 |
| Simon, A | 1 |
| Guardiola, M | 1 |
| Murri, M | 1 |
| Ribalta, J | 1 |
| Jastrzebska, M | 1 |
| Chełstowski, K | 1 |
| Mierzecki, A | 1 |
| Klimek, K | 1 |
| Bukowska, H | 1 |
| Winkler, K | 1 |
| Schewe, T | 1 |
| Pütz, G | 1 |
| Odünc, N | 1 |
| Schäfer, G | 1 |
| Siegel, E | 1 |
| Geisen, U | 1 |
| Abletshauser, C | 1 |
| Hoffmann, MM | 1 |
| Toth, PP | 1 |
| Rye, KA | 2 |
| Westerink, J | 1 |
| Visseren, FL | 1 |
| Belfort, R | 1 |
| Berria, R | 1 |
| Cornell, J | 1 |
| Cusi, K | 2 |
| Sandoval, JC | 1 |
| Nakagawa-Toyama, Y | 1 |
| Masuda, D | 1 |
| Tochino, Y | 1 |
| Nakaoka, H | 1 |
| Kawase, R | 1 |
| Yuasa-Kawase, M | 1 |
| Nakatani, K | 1 |
| Inagaki, M | 1 |
| Tsubakio-Yamamoto, K | 1 |
| Ohama, T | 1 |
| Nishida, M | 1 |
| Ishigami, M | 1 |
| Komuro, I | 1 |
| Yamashita, S | 1 |
| Kraja, AT | 1 |
| Province, MA | 2 |
| Straka, RJ | 3 |
| Ordovas, JM | 3 |
| Borecki, IB | 2 |
| Arnett, DK | 3 |
| Bays, HE | 3 |
| Roth, EM | 1 |
| McKenney, JM | 1 |
| Kelly, MT | 1 |
| Thakker, KM | 1 |
| Setze, CM | 1 |
| Obermeyer, K | 1 |
| Sleep, DJ | 1 |
| Krysiak, R | 1 |
| Gdula-Dymek, A | 1 |
| Bachowski, R | 1 |
| Okopien, B | 2 |
| Agouridis, AP | 2 |
| Filippatos, TD | 4 |
| Derdemezis, CS | 1 |
| Mikhailidis, DP | 7 |
| Elisaf, MS | 6 |
| Helenowski, IB | 3 |
| Tangney, CC | 1 |
| Shah, A | 1 |
| Macdonell, G | 1 |
| Taggart, WV | 1 |
| Gumbiner, B | 1 |
| Paraskevas, KI | 1 |
| Pantopoulou, A | 1 |
| Vlachos, IS | 1 |
| Agrogiannis, G | 1 |
| Iliopoulos, DG | 1 |
| Karatzas, G | 1 |
| Tzivras, D | 1 |
| Perrea, DN | 1 |
| Feitosa, MF | 1 |
| An, P | 1 |
| Ketkar, S | 1 |
| Hopkins, PN | 1 |
| Chen, W | 1 |
| Zhang, LH | 1 |
| Liu, HY | 1 |
| Zhou, XB | 1 |
| Wang, LL | 1 |
| Bragt, MC | 1 |
| Mensink, RP | 1 |
| Donoghoe, M | 1 |
| Davis, TM | 1 |
| Colman, PG | 1 |
| Manning, P | 1 |
| Keech, AC | 1 |
| Vakhrushev, IaM | 1 |
| Volkova, AA | 1 |
| Kostapanos, MS | 1 |
| Tsimihodimos, V | 1 |
| Kostara, C | 1 |
| Bairaktari, ET | 1 |
| Tselepis, AD | 3 |
| Ng, TW | 1 |
| Serone, AP | 1 |
| Croft, KD | 1 |
| Loehrer, F | 1 |
| Vega, GL | 1 |
| Ma, PT | 1 |
| Cater, NB | 1 |
| Filipchuk, N | 1 |
| Meguro, S | 1 |
| Garcia-Garcia, AB | 1 |
| Grundy, SM | 1 |
| Cottrell, DA | 1 |
| Marshall, BJ | 1 |
| Falko, JM | 1 |
| Mamedov, MN | 1 |
| Perova, NV | 1 |
| Kosmatova, OV | 1 |
| Khadipash, LA | 1 |
| Kiseleva, NV | 1 |
| Oganov, RG | 1 |
| Maki, KC | 2 |
| Hepburn, AL | 1 |
| Feher, MD | 1 |
| Wysocki, J | 1 |
| Belowski, D | 1 |
| Kalina, M | 1 |
| Kochanski, L | 1 |
| Kalina, Z | 1 |
| Gavrila, A | 1 |
| Hsu, W | 1 |
| Tsiodras, S | 1 |
| Doweiko, J | 1 |
| Gautam, S | 1 |
| Martin, L | 1 |
| Moses, AC | 1 |
| Karchmer, AW | 1 |
| Mantzoros, CS | 1 |
| Koh, KK | 1 |
| Han, SH | 1 |
| Quon, MJ | 1 |
| Yeal Ahn, J | 1 |
| Shin, EK | 1 |
| Athyros, VG | 4 |
| Elisaf, M | 2 |
| Papageorgiou, AA | 1 |
| Didangelos, TP | 2 |
| Peletidou, A | 1 |
| Kleta, D | 1 |
| Karagiannis, A | 2 |
| Kakafika, AI | 2 |
| Tziomalos, K | 2 |
| Davidson, MH | 3 |
| Bays, H | 1 |
| Rhyne, J | 1 |
| Stein, E | 2 |
| Rotenberg, K | 1 |
| Doyle, R | 2 |
| Nesto, RW | 1 |
| Kiortsis, DN | 3 |
| Liberopoulos, EN | 4 |
| Georgoula, M | 1 |
| Srivastava, RA | 1 |
| Jahagirdar, R | 1 |
| Azhar, S | 1 |
| Sharma, S | 1 |
| Bisgaier, CL | 1 |
| Giouleme, OI | 1 |
| Burroughs, AK | 1 |
| Shalwitz, RA | 1 |
| Gazi, IF | 2 |
| Hiuge, A | 1 |
| Tenenbaum, A | 1 |
| Maeda, N | 1 |
| Benderly, M | 1 |
| Kumada, M | 1 |
| Fisman, EZ | 1 |
| Tanne, D | 1 |
| Matas, Z | 1 |
| Hibuse, T | 1 |
| Fujita, K | 1 |
| Nishizawa, H | 1 |
| Adler, Y | 1 |
| Motro, M | 1 |
| Kihara, S | 1 |
| Shimomura, I | 1 |
| Behar, S | 1 |
| Funahashi, T | 1 |
| Keating, GM | 1 |
| Croom, KF | 1 |
| Kostapanos, M | 1 |
| Papavasiliou, EC | 1 |
| Wolff, DA | 2 |
| Huskin, AL | 2 |
| Rademaker, AW | 2 |
| Zvenigorodskaia, LA | 1 |
| Mel'nikova, NV | 1 |
| Bondarenko, EIu | 1 |
| Rosolová, H | 1 |
| Bláha, V | 1 |
| Ceska, R | 1 |
| Hamouz, Z | 1 |
| Pelikánová, T | 1 |
| Soska, V | 1 |
| Soucek, M | 1 |
| Sucharda, P | 1 |
| Takahashi, S | 1 |
| Inokuchi, T | 1 |
| Kobayashi, T | 1 |
| Ka, T | 1 |
| Tsutsumi, Z | 1 |
| Moriwaki, Y | 1 |
| Yamamoto, T | 1 |
| Plutzky, J | 1 |
| Zambon, A | 1 |
| Shen, J | 1 |
| Parnell, LD | 1 |
| Peacock, JM | 1 |
| Lai, CQ | 1 |
| Hixson, JE | 1 |
| Tsai, MY | 1 |
| Cannon, CP | 1 |
| Kilicarslan, A | 1 |
| Yavuz, B | 1 |
| Guven, GS | 1 |
| Atalar, E | 1 |
| Sahiner, L | 1 |
| Beyazit, Y | 1 |
| Kekilli, M | 1 |
| Ozer, N | 1 |
| Oz, G | 1 |
| Haznedaroglu, IC | 1 |
| Sozen, T | 1 |
| Idzior-Waluś, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Double-Blind Study Comparing the Efficacy and Safety of 145 mg Fenofibrate, 10 mg Ezetimibe and Their Combination in Patients With Type IIb Dyslipidemia and Features of the Metabolic Syndrome[NCT00349284] | Phase 3 | 181 participants | Interventional | 2005-01-31 | Completed | ||
| Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate With the Metabolic Syndrome[NCT00632840] | Phase 4 | 11 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of Fenofibric Acid and Atorvastatin Calcium Combination Therapy to Fenofibric Acid and Atorvastatin Calcium Monotherapy in Subjects With Mixed Dyslipidemia[NCT00300469] | Phase 3 | 613 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of Fenofibric Acid and Rosuvastatin Calcium Combination Therapy to Fenofibric Acid and Rosuvastatin Calcium Monotherapy in Subjects With Mixed Dyslipidemia[NCT00300482] | Phase 3 | 1,445 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of ABT-335 and Simvastatin Combination Therapy to ABT-335 and Simvastatin Monotherapy in Subjects With Mixed Dyslipidemia[NCT00300456] | Phase 3 | 657 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Effects of Fenofibrate on Metabolic and Reproductive Parameters in Polycystic Ovary Syndrome. A Randomized, Double-Blind, Placebo-Controlled Trial[NCT00884819] | 4 participants (Actual) | Interventional | 2008-12-31 | Terminated (stopped due to Poor recruitment) | |||
| Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT)[NCT00416741] | 2,000 participants (Actual) | Observational | 2005-02-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
[(Week 12 HDL-C minus baseline HDL-C)/baseline HDL-C] x 100 (NCT00300469)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Atorvastatin | 14.0 |
| ABT-335 + 40 mg Atorvastatin | 12.6 |
| ABT-335 | 19.9 |
| 20 mg Atorvastatin | 6.3 |
| 40 mg Atorvastatin | 5.3 |
| 80 mg Atorvastatin | 6.2 |
[(Week 12 Apo B minus baseline Apo B)/baseline Apo B] x 100 (NCT00300469)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Atorvastatin | -37.0 |
| ABT-335 + 40 mg Atorvastatin | -37.1 |
| ABT-335 | -12.4 |
| 20 mg Atorvastatin | -32.9 |
| 40 mg Atorvastatin | -35.3 |
| 80 mg Atorvastatin | -40.3 |
[(Week 12 LDL-C minus baseline LDL-C)/baseline LDL-C] x 100 (NCT00300469)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Atorvastatin | -33.7 |
| ABT-335 + 40 mg Atorvastatin | -35.4 |
| ABT-335 | -3.4 |
| 20 mg Atorvastatin | -37.1 |
| 40 mg Atorvastatin | -39.7 |
| 80 mg Atorvastatin | -46.0 |
[(Week 12 non-HDL-C minus baseline non-HDL-C)/baseline non-HDL-C] x 100 (NCT00300469)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Atorvastatin | -40.8 |
| ABT-335 + 40 mg Atorvastatin | -42.5 |
| ABT-335 | -14.8 |
| 20 mg Atorvastatin | -35.7 |
| 40 mg Atorvastatin | -41.7 |
| 80 mg Atorvastatin | -45.2 |
[(Week 12 total cholesterol minus baseline total cholesterol)/baseline total cholesterol] x 100 (NCT00300469)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Atorvastatin | -32.8 |
| ABT-335 + 40 mg Atorvastatin | -34.6 |
| ABT-335 | -10.1 |
| 20 mg Atorvastatin | -29.6 |
| 40 mg Atorvastatin | -33.8 |
| 80 mg Atorvastatin | -38.2 |
[(Week 12 triglycerides minus baseline triglycerides)/baseline triglycerides] x 100 (NCT00300469)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Atorvastatin | -45.6 |
| ABT-335 + 40 mg Atorvastatin | -42.1 |
| ABT-335 | -29.6 |
| 20 mg Atorvastatin | -16.5 |
| 40 mg Atorvastatin | -23.2 |
| 80 mg Atorvastatin | -30.4 |
[(Week 12 VLDL-C minus baseline VLDL-C)/baseline VLDL-C] x 100 (NCT00300469)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Atorvastatin | -48.3 |
| ABT-335 + 40 mg Atorvastatin | -53.5 |
| ABT-335 | -36.5 |
| 20 mg Atorvastatin | -26.2 |
| 40 mg Atorvastatin | -35.6 |
| 80 mg Atorvastatin | -38.9 |
[(Week 12 hsCRP minus baseline hsCRP)/baseline hsCRP] x 100 (NCT00300469)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Median) |
|---|---|
| ABT-335 + 20 mg Atorvastatin | -26.2 |
| ABT-335 + 40 mg Atorvastatin | -42.9 |
| ABT-335 | -12.4 |
| 20 mg Atorvastatin | -29.6 |
| 40 mg Atorvastatin | -30.3 |
| 80 mg Atorvastatin | -31.9 |
[(Week 12 HDL-C minus baseline HDL-C)/baseline HDL-C] x 100 (NCT00300482)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 10 mg Rosuvastatin | 20.3 |
| ABT-335 + 20 mg Rosuvastatin | 19.0 |
| ABT-335 | 15.0 |
| 10 mg Rosuvastatin | 8.5 |
| 20 mg Rosuvastatin | 10.3 |
| 40 mg Rosuvastatin | 9.3 |
[(Week 12 Apo B minus baseline Apo B)/baseline Apo B] x 100 (NCT00300482)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 10 mg Rosuvastatin | -39.2 |
| ABT-335 + 20 mg Rosuvastatin | -39.2 |
| ABT-335 | -16.2 |
| 10 mg Rosuvastatin | -34.1 |
| 20 mg Rosuvastatin | -39.6 |
| 40 mg Rosuvastatin | -45.0 |
[(Week 12 LDL-C minus baseline LDL-C)/baseline LDL-C] x 100 (NCT00300482)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 10 mg Rosuvastatin | -37.2 |
| ABT-335 + 20 mg Rosuvastatin | -38.8 |
| ABT-335 | -6.5 |
| 10 mg Rosuvastatin | -38.0 |
| 20 mg Rosuvastatin | -45.0 |
| 40 mg Rosuvastatin | -50.6 |
[(Week 12 non-HDL-C minus baseline non-HDL-C)/baseline non-HDL-C] x 100 (NCT00300482)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 10 mg Rosuvastatin | -44.7 |
| ABT-335 + 20 mg Rosuvastatin | -45.3 |
| ABT-335 | -18.5 |
| 10 mg Rosuvastatin | -39.8 |
| 20 mg Rosuvastatin | -45.8 |
| 40 mg Rosuvastatin | -51.5 |
[(Week 12 total cholesterol minus baseline total cholesterol)/baseline total cholesterol] x 100 (NCT00300482)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 10 mg Rosuvastatin | -34.4 |
| ABT-335 + 20 mg Rosuvastatin | -35.7 |
| ABT-335 | -13.5 |
| 10 mg Rosuvastatin | -32.5 |
| 20 mg Rosuvastatin | -37.3 |
| 40 mg Rosuvastatin | -42.7 |
[(Week 12 triglycerides minus baseline triglycerides)/baseline triglycerides] x 100 (NCT00300482)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 10 mg Rosuvastatin | -47.1 |
| ABT-335 + 20 mg Rosuvastatin | -42.9 |
| ABT-335 | -32.6 |
| 10 mg Rosuvastatin | -24.4 |
| 20 mg Rosuvastatin | -25.6 |
| 40 mg Rosuvastatin | -32.1 |
[(Week 12 VLDL-C minus baseline VLDL-C)/baseline VLDL-C] x 100 (NCT00300482)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 10 mg Rosuvastatin | -55.8 |
| ABT-335 + 20 mg Rosuvastatin | -50.6 |
| ABT-335 | -31.9 |
| 10 mg Rosuvastatin | -41.0 |
| 20 mg Rosuvastatin | -42.1 |
| 40 mg Rosuvastatin | -49.1 |
[(Week 12 hsCRP minus baseline hsCRP)/baseline hsCRP] x 100 (NCT00300482)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Median) |
|---|---|
| ABT-335 + 10 mg Rosuvastatin | -33.8 |
| ABT-335 + 20 mg Rosuvastatin | -40.8 |
| ABT-335 | -12.1 |
| 10 mg Rosuvastatin | -22.9 |
| 20 mg Rosuvastatin | -29.9 |
| 40 mg Rosuvastatin | -33.1 |
[(Week 12 HDL-C minus baseline HDL-C)/baseline HDL-C] x 100 (NCT00300456)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Simvastatin | 17.8 |
| ABT-335 + 40 mg Simvastatin | 18.9 |
| ABT-335 | 16.2 |
| 20 mg Simvastatin | 7.2 |
| 40 mg Simvastatin | 8.5 |
| 80 mg Simvastatin | 6.8 |
[(Week 12 Apo B minus baseline Apo B)/baseline Apo B] x 100 (NCT00300456)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Simvastatin | -29.5 |
| ABT-335 + 40 mg Simvastatin | -31.2 |
| ABT-335 | -17.6 |
| 20 mg Simvastatin | -22.9 |
| 40 mg Simvastatin | -32.7 |
| 80 mg Simvastatin | -38.9 |
[(Week 12 LDL-C minus baseline LDL-C)/baseline LDL-C] x 100 (NCT00300456)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Simvastatin | -24.0 |
| ABT-335 + 40 mg Simvastatin | -25.3 |
| ABT-335 | -4.0 |
| 20 mg Simvastatin | -22.4 |
| 40 mg Simvastatin | -31.7 |
| 80 mg Simvastatin | -40.8 |
[(Week 12 non-HDL-C minus baseline non-HDL-C)/baseline non-HDL-C] x 100 (NCT00300456)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Simvastatin | -30.7 |
| ABT-335 + 40 mg Simvastatin | -35.0 |
| ABT-335 | -17.3 |
| 20 mg Simvastatin | -24.4 |
| 40 mg Simvastatin | -35.9 |
| 80 mg Simvastatin | -40.6 |
[(Week 12 total cholesterol minus baseline total cholesterol)/baseline total cholesterol] x 100 (NCT00300456)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Simvastatin | -23.9 |
| ABT-335 + 40 mg Simvastatin | -27.1 |
| ABT-335 | -12.4 |
| 20 mg Simvastatin | -19.8 |
| 40 mg Simvastatin | -30.0 |
| 80 mg Simvastatin | -33.6 |
[(Week 12 triglycerides minus baseline triglycerides)/baseline triglycerides] x 100 (NCT00300456)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Simvastatin | -37.4 |
| ABT-335 + 40 mg Simvastatin | -42.7 |
| ABT-335 | -31.7 |
| 20 mg Simvastatin | -14.2 |
| 40 mg Simvastatin | -22.4 |
| 80 mg Simvastatin | -20.2 |
[(Week 12 VLDL-C minus baseline VLDL-C)/baseline VLDL-C] x 100 (NCT00300456)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Simvastatin | -38.9 |
| ABT-335 + 40 mg Simvastatin | -51.1 |
| ABT-335 | -36.9 |
| 20 mg Simvastatin | -19.2 |
| 40 mg Simvastatin | -35.7 |
| 80 mg Simvastatin | -30.0 |
[(Week 12 hsCRP minus baseline hsCRP)/baseline hsCRP] x 100 (NCT00300456)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Median) |
|---|---|
| ABT-335 + 20 mg Simvastatin | -26.8 |
| ABT-335 + 40 mg Simvastatin | -32.1 |
| ABT-335 | -15.8 |
| 20 mg Simvastatin | -11.4 |
| 40 mg Simvastatin | -14.8 |
| 80 mg Simvastatin | -19.8 |
17 reviews available for fenofibrate and Cardiometabolic Syndrome
| Article | Year |
|---|---|
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Topics: Animals; Anticholesteremic Agents; Drug Delivery Systems; Drug Development; Humans; Hypoglycemic Age | 2020 |
PPARα: An emerging target of metabolic syndrome, neurodegenerative and cardiovascular diseases.
Topics: Cardiovascular Diseases; Fenofibrate; Humans; Metabolic Syndrome; Neurodegenerative Diseases; PPAR a | 2022 |
[Diabetic dyslipidaemia and the atherosclerosis].
Topics: Apolipoprotein A-V; Apolipoproteins A; Apolipoproteins C; Atherosclerosis; Cardiovascular Diseases; | 2016 |
Combination statin-fibrate therapy: safety aspects.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination | 2009 |
Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
Topics: Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Fenofibrat | 2008 |
Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug | 2008 |
Clinical insights from the Fenofibrate Intervention and Event Lowering in Diabetes study: a community practice perspective.
Topics: Community Health Services; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combinati | 2009 |
Fenofibrate and metabolic syndrome.
Topics: Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Fenofibrate; Humans; Hydroxymethylglu | 2010 |
Combination of fenofibrate with non-statin drug regimens.
Topics: Animals; Drug Therapy, Combination; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibit | 2010 |
Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopat | 2003 |
Fibrates for treatment of the metabolic syndrome.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Clofibrate; Fenofibrate; Gemfibrozil; Humans; Hyp | 2004 |
Role of fibrates in reducing coronary risk: a UK Consensus.
Topics: Bezafibrate; Cholesterol, HDL; Coronary Disease; Drug Therapy, Combination; Fenofibrate; Gemfibrozil | 2004 |
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diet; Drug T | 2005 |
Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
Topics: Area Under Curve; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Dr | 2006 |
Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic Agents; Metabolic Syndr | 2007 |
Combination therapy in the management of mixed dyslipidaemia.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Routes; Dr | 2008 |
[Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome].
Topics: Cardiovascular Diseases; Clofibrate; Fenofibrate; Hemostasis; Humans; Hyperinsulinism; Hyperlipidemi | 2001 |
39 trials available for fenofibrate and Cardiometabolic Syndrome
| Article | Year |
|---|---|
Effect of ABT-335 (fenofibric acid) on meal-induced oxidative stress in patients with metabolic syndrome.
Topics: Adult; Aged; Anticholesteremic Agents; Antioxidants; Cholesterol, HDL; Cholesterol, LDL; Copper; Cro | 2013 |
Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome.
Topics: Cells, Cultured; Cholesterol, HDL; Cross-Over Studies; Delayed-Action Preparations; Endothelial Cell | 2015 |
Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.
Topics: Adult; Apolipoprotein C-III; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Cholesterol; Cross- | 2008 |
Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Humans; Hypo | 2009 |
Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients.
Topics: Adiponectin; Adult; Aged; Biomarkers; C-Reactive Protein; Chemokine CCL2; Chemokine CCL3; Female; Fe | 2009 |
Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter,
Topics: Anticholesteremic Agents; Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Fem | 2009 |
Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Drug Administration | 2009 |
Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndrome.
Topics: Atorvastatin; Cross-Over Studies; Double-Blind Method; Fenofibrate; Heptanoic Acids; Humans; Hydroxy | 2009 |
Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome.
Topics: Adult; C-Reactive Protein; Double-Blind Method; Fatty Acids, Nonesterified; Female; Fenofibrate; Glu | 2010 |
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
Topics: Dyslipidemias; Fenofibrate; Hypolipidemic Agents; Metabolic Syndrome; Simvastatin | 2010 |
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
Topics: Dyslipidemias; Fenofibrate; Hypolipidemic Agents; Metabolic Syndrome; Simvastatin | 2010 |
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
Topics: Dyslipidemias; Fenofibrate; Hypolipidemic Agents; Metabolic Syndrome; Simvastatin | 2010 |
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
Topics: Dyslipidemias; Fenofibrate; Hypolipidemic Agents; Metabolic Syndrome; Simvastatin | 2010 |
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
Topics: Dyslipidemias; Fenofibrate; Hypolipidemic Agents; Metabolic Syndrome; Simvastatin | 2010 |
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
Topics: Dyslipidemias; Fenofibrate; Hypolipidemic Agents; Metabolic Syndrome; Simvastatin | 2010 |
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
Topics: Dyslipidemias; Fenofibrate; Hypolipidemic Agents; Metabolic Syndrome; Simvastatin | 2010 |
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
Topics: Dyslipidemias; Fenofibrate; Hypolipidemic Agents; Metabolic Syndrome; Simvastatin | 2010 |
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
Topics: Dyslipidemias; Fenofibrate; Hypolipidemic Agents; Metabolic Syndrome; Simvastatin | 2010 |
Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cytokines; Factor VII; Fenofibrate; Fibr | 2010 |
Heterogeneous postprandial lipoprotein responses in the metabolic syndrome, and response to fenofibrate therapy.
Topics: Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Double-Blind Method; Female; Fenofibrate; Hum | 2010 |
Effects of coadministered ezetimibe plus fenofibrate in mixed dyslipidemic patients with metabolic syndrome.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol, LDL; | 2011 |
Comparison of the effects of n-3 long chain polyunsaturated fatty acids and fenofibrate on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects.
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Chemokine CCL2; Cholesterol, HDL; Cholesterol, LDL | 2012 |
Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial.
Topics: Aged; Australia; Cardiovascular Diseases; Cholesterol, HDL; Cohort Studies; Diabetes Mellitus, Type | 2011 |
Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome.
Topics: Apolipoproteins; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Fatty | 2012 |
Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome.
Topics: Adult; Apolipoproteins B; Apolipoproteins E; Atorvastatin; Double-Blind Method; Fenofibrate; Heptano | 2012 |
Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
Topics: Adult; Apolipoprotein A-I; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Blood Glucose; Cho | 2003 |
Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
Topics: Adult; Aged; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Double-Blind Metho | 2003 |
Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome.
Topics: Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Insul | 2004 |
Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Double-Blind Method; Fenofibrate; Humans; Hy | 2005 |
Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia.
Topics: Adiponectin; Blood Flow Velocity; Body Mass Index; Brachial Artery; Cross-Over Studies; Double-Blind | 2005 |
Inflammatory markers and the metabolic syndrome.
Topics: Antihypertensive Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Drug | 2005 |
Targeting vascular risk in patients with metabolic syndrome but without diabetes.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Diabetes Mellitus; Drug Therapy, C | 2005 |
Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study.
Topics: Capsules; Cholesterol, HDL; Cholesterol, VLDL; Diarrhea; Double-Blind Method; Drug Administration Sc | 2005 |
Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study.
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Fenofibrate; Hum | 2005 |
Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome.
Topics: Adult; Apolipoprotein B-100; Cholesterol; Cholesterol Ester Transfer Proteins; Cross-Over Studies; D | 2006 |
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.
Topics: Anti-Obesity Agents; Atorvastatin; Diet, Fat-Restricted; Drug Therapy, Combination; Dyslipidemias; F | 2006 |
Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects.
Topics: Adult; Aged; Atherosclerosis; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Fenofibr | 2006 |
The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Anti-Obesity Agents; Cardiovascular Diseases; | 2007 |
Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level.
Topics: Adipocytes; Adiponectin; Adult; Analysis of Variance; Animals; Bezafibrate; Cells, Cultured; Disease | 2007 |
The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome.
Topics: Anti-Obesity Agents; Body Mass Index; Cholesterol, HDL; Drug Therapy, Combination; Female; Fenofibra | 2008 |
Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.
Topics: Adult; Apolipoproteins B; Blood Glucose; Blood Pressure; Double-Blind Method; Fatty Acids, Nonesteri | 2007 |
[Pleiotropic effects of fibric acid derivatives (Lipanthyl-200) among patients with metabolic syndrome].
Topics: Carbohydrate Metabolism; Clofibric Acid; Female; Fenofibrate; Humans; Hypercholesterolemia; Hypolipi | 2007 |
Relationship between insulin resistance and low urinary pH in patients with gout, and effects of PPARalpha agonists on urine pH.
Topics: Bezafibrate; Biomarkers; Body Mass Index; Fenofibrate; Gout; Humans; Hydrogen-Ion Concentration; Hyp | 2007 |
Normalization of metabolic syndrome using fenofibrate, metformin or their combination.
Topics: Adolescent; Adult; Aged; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dose-Response R | 2007 |
Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome.
Topics: Aged; Cytokines; Double-Blind Method; Fasting; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hy | 2008 |
Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Dose-Response Relationship, Drug; Double-Blin | 2008 |
Fenofibrate improves endothelial function and decreases thrombin-activatable fibrinolysis inhibitor concentration in metabolic syndrome.
Topics: Adult; Carboxypeptidase B2; Endothelium, Vascular; Female; Fenofibrate; Fibrinogen; Humans; Hypolipi | 2008 |
30 other studies available for fenofibrate and Cardiometabolic Syndrome
| Article | Year |
|---|---|
Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
Topics: 3T3-L1 Cells; AMP-Activated Protein Kinases; Animals; Chalcones; Chemistry Techniques, Synthetic; He | 2020 |
Continuation of fibrate therapy in patients with metabolic syndrome and COVID-19: a beneficial regime worth pursuing.
Topics: COVID-19 Drug Treatment; Fenofibrate; Fibric Acids; Guidelines as Topic; Humans; Metabolic Syndrome; | 2022 |
Disentangling Genetic Risks for Metabolic Syndrome.
Topics: Blood Glucose; Blood Pressure; Cholesterol, HDL; Diabetes Mellitus, Type 2; Fenofibrate; Genome-Wide | 2022 |
Addition of fenofibrate to statins is associated with risk reduction of diabetic retinopathy progression in patients with type 2 diabetes and metabolic syndrome: A propensity-matched cohort study.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fenofibrate; Humans; Hydroxymethylg | 2023 |
Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study.
Topics: Adult; Aged; Cardiovascular Diseases; Cause of Death; Cohort Studies; Drug Therapy, Combination; Fem | 2019 |
Prolonged overnutrition with fructose or fat induces metabolic derangements in rats by disrupting the crosstalk between the hypothalamus and periphery: Possible amelioration with fenofibrate.
Topics: Adipose Tissue, White; Animals; Brain; Diet, High-Fat; Dietary Sugars; Fatty Acids, Nonesterified; F | 2020 |
PPARα-independent action against metabolic syndrome development by fibrates is mediated by inhibition of STAT3 signalling.
Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Body Weight; Fenofibrate; Fibric Acids; Gemfibrozil; Glucose | 2018 |
APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Apolipoprotein E3; Atorvastatin; Cholesterol E | 2014 |
Ursodeoxycholic acid ameliorates fructose-induced metabolic syndrome in rats.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Fenofibrate; Fructose; Glutathione | 2014 |
Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience.
Topics: Adolescent; Carbohydrates; Child; Child, Preschool; Craniopharyngioma; Dyslipidemias; Female; Fenofi | 2015 |
Hepatotoxic effects of fenofibrate in spontaneously hypertensive rats expressing human C-reactive protein.
Topics: Adipose Tissue; Animals; C-Reactive Protein; Chemical and Drug Induced Liver Injury; Fenofibrate; Gl | 2016 |
Fenofibrate Therapy Restores Antioxidant Protection and Improves Myocardial Insulin Resistance in a Rat Model of Metabolic Syndrome and Myocardial Ischemia: The Role of Angiotensin II.
Topics: Angiotensin II; Animals; Antioxidants; Catalase; Disease Models, Animal; Fenofibrate; Insulin; Insul | 2016 |
Molecular effect of fenofibrate on PBMC gene transcription related to lipid metabolism in patients with metabolic syndrome.
Topics: Adult; Apolipoproteins; Female; Fenofibrate; Humans; Hypolipidemic Agents; Leukocytes, Mononuclear; | 2017 |
Kinetic studies of the metabolism of rapidly exchangeable apolipoproteins may leave investigators and readers with exchangeable results.
Topics: Apolipoprotein C-III; Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Cholester | 2008 |
Reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering: a role for fenofibrate. Introduction.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fenofibrate; Humans; Hypolipidemic Agents; Metab | 2008 |
The -1131T>C SNP of the APOA5 gene modulates response to fenofibrate treatment in patients with the metabolic syndrome: a postprandial study.
Topics: Adult; Apolipoprotein A-V; Apolipoproteins A; Dietary Fats; Female; Fenofibrate; Humans; Hypertrigly | 2009 |
Effects of fenofibrate treatment on prothrombotic state in patients with metabolic syndrome in relation to smoking and diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Male; Metabolic Syndrome; Middle Aged | 2009 |
Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combi | 2010 |
Fenofibrate reduces postprandial hypertriglyceridemia in CD36 knockout mice.
Topics: Animals; CD36 Antigens; Chylomicrons; Fenofibrate; Hypertriglyceridemia; Intestinal Mucosa; Metaboli | 2010 |
Comparison of fibrate, ezetimibe, low- and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model.
Topics: Animals; Atorvastatin; Azetidines; Disease Models, Animal; Dose-Response Relationship, Drug; Dyslipi | 2011 |
Association of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome status.
Topics: Adult; Aged; Apolipoprotein A-V; Apolipoproteins A; Apolipoproteins E; Cholesterol, HDL; Cholesterol | 2011 |
Combination of fenofibrate and rosiglitazone synergistically ameliorate dyslipidemia and insulin resistance in mice with MSG metabolic syndrome.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipose Tissue, White; Animals; Animals, Newborn; Blood | 2010 |
[Differentiated approaches to the treatment of chronic pancreatitis patients with metabolic syndrome].
Topics: Adult; Aged; Carbohydrate Metabolism; Drug Therapy, Combination; Female; Fenofibrate; Gastrointestin | 2011 |
[Effect of combined antihypertensive and lipid lowering therapy on the level of coronary risk and tissue insulin resistance in patients with metabolic syndrome].
Topics: Adult; Antihypertensive Agents; Atenolol; Atorvastatin; Blood Pressure; Cholesterol, HDL; Cholestero | 2003 |
Gout.
Topics: Coronary Disease; Fenofibrate; Gout; Humans; Hypolipidemic Agents; Metabolic Syndrome; Risk Factors; | 2004 |
Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice.
Topics: Adiposity; Animals; Aorta; Coronary Artery Disease; Diet, Atherogenic; Energy Metabolism; Fenofibrat | 2006 |
[The effect of treatment with fenofibrate on the risk profile of patients with metabolic syndrome and mixed dyslipidemia treated on an outpatient basis].
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol; Cholest | 2007 |
Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: the role of PPARalpha.
Topics: Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fatty Liver; Fen | 2007 |
The role of fenofibrate in clinical practice.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination | 2007 |
Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: the GOLDN study.
Topics: Adult; Aged; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; DNA; Female; Fenofibrate; Genet | 2008 |